Table 5 Safety on varicella vaccination

Crespo JF, et al. (2002) [16]

-17 seronegative patients completed vaccination protocol.

-No secondary effect of vaccination detected.

-None of the subsequently seroconverted patients who received kidney transplant presented with VZV disease (up to 18 months post renal transplant).

-Systematic vaccination prior to transplantation could prevent severe varicella.

Level 2

Scanlon-Kohlroser CA,et al. (2002) [28]

-A single case of 51yo woman at 6 months post-renal transplant developed a mild rash.

-She had daily household contact with 15-month old twins vaccinated 40 days ago.

-Characteristic popular and vesicular rash over the face, trunk, extremities. No dissemination. Confirmed with positive VZV IgG 2 weeks later.

-Transmission from those vaccinated to susceptible individuals are rare and typically occurs only if these patients develop a rash.

- Contact cases develop a subclinical infection or mild illness; suggesting vaccine virus remains attenuated when vaccinated.

Level 3

Geel AL, et al. (2006) [17]

-11 seronegative patients have been vaccinated with two doses VZV vaccine.

- No side effects, no fever, or skin lesions among all vaccinated patients.

-Vaccination should be performed in this group of patients in view of potentially lethal complications of primary varicella infection.

Level 2

Kho MML, et al. (2016) [32]

-52 seronegative patients given two doses of VZV vaccine.

-No severe vaccine-related adverse events were reported.

- One had pain at injection site.

-Two had zoster (3 months and 9 years post vaccination)

-One patient developed mild varicella (18 days post vaccination).

Level 2